Aprea's eprenetapopt Fast Track'd for type of blood cancer

 

• The FDA grants Fast Track status to Aprea Therapeutics' (NASDAQ:APRE) eprenetapopt for the treatment of acute myeloid leukemia (AML).
• Fast Track provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.
• Small molecule eprenetapopt reactivates a tumor suppressor protein called p53 thereby inducing programmed cell death in cancer cells.
• https://seekingalpha.com/news/3639945-apreas-eprenetapopt-fast-trackd-for-type-of-blood-cancer